129 related articles for article (PubMed ID: 23183521)
21. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
Kumada H; Suzuki F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Fujiyama S; Ito T; Itoh Y; Tamura E; Ueki T; Ishikawa H; Hu W; McPhee F; Linaberry M; Hughes E
J Gastroenterol Hepatol; 2016 Jan; 31(1):14-22. PubMed ID: 26252875
[TBL] [Abstract][Full Text] [Related]
22. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
[TBL] [Abstract][Full Text] [Related]
23. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
Flamm SL; Lawitz E; Jacobson I; Bourlière M; Hezode C; Vierling JM; Bacon BR; Niederau C; Sherman M; Goteti V; Sings HL; Barnard RO; Howe JA; Pedicone LD; Burroughs MH; Brass CA; Albrecht JK; Poordad F
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222
[TBL] [Abstract][Full Text] [Related]
24. [Retreatment options for patients with chronic hepatitis C].
Hrstić I; Ostojić R; Vucelić B
Acta Med Croatica; 2009 Dec; 63(5):417-22. PubMed ID: 20198901
[TBL] [Abstract][Full Text] [Related]
25. Telaprevir for previously treated chronic HCV infection.
McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM;
N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406
[TBL] [Abstract][Full Text] [Related]
26. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.
Manns M; Reesink H; Berg T; Dusheiko G; Flisiak R; Marcellin P; Moreno C; Lenz O; Meyvisch P; Peeters M; Sekar V; Simmen K; Verloes R
Antivir Ther; 2011; 16(7):1021-33. PubMed ID: 22024518
[TBL] [Abstract][Full Text] [Related]
27. Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
Colombo M; Strasser S; Moreno C; Abrao Ferreira P; Urbanek P; Fernández I; Abdurakmonov D; Streinu-Cercel A; Verheyen A; Iraqi W; DeMasi R; Hill A; Lonjon-Domanec I; Wedemeyer H
J Hepatol; 2014 Nov; 61(5):976-83. PubMed ID: 24946280
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response.
Furusyo N; Ogawa E; Murata M; Toyoda K; Ohnishi H; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Kainuma M; Okada K; Hayashi J
J Antimicrob Chemother; 2014 Feb; 69(2):483-90. PubMed ID: 24092661
[TBL] [Abstract][Full Text] [Related]
29. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
[TBL] [Abstract][Full Text] [Related]
31. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
Rodriguez-Torres M; Lawitz E; Kowdley KV; Nelson DR; Dejesus E; McHutchison JG; Cornpropst MT; Mader M; Albanis E; Jiang D; Hebner CM; Symonds WT; Berrey MM; Lalezari J
J Hepatol; 2013 Apr; 58(4):663-8. PubMed ID: 23183528
[TBL] [Abstract][Full Text] [Related]
32. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
[TBL] [Abstract][Full Text] [Related]
33. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
34. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.
Buti M; Lurie Y; Zakharova NG; Blokhina NP; Horban A; Teuber G; Sarrazin C; Balciuniene L; Feinman SV; Faruqi R; Pedicone LD; Esteban R;
Hepatology; 2010 Oct; 52(4):1201-7. PubMed ID: 20683847
[TBL] [Abstract][Full Text] [Related]
36. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
Benhamou Y; Moussalli J; Ratziu V; Lebray P; De Backer K; De Meyer S; Ghys A; Luo D; Picchio GR; Beumont M
J Infect Dis; 2013 Sep; 208(6):1000-7. PubMed ID: 23801602
[TBL] [Abstract][Full Text] [Related]
37. Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients.
Nair S; Waters B
Exp Clin Transplant; 2014 Apr; 12(2):117-22. PubMed ID: 24702143
[TBL] [Abstract][Full Text] [Related]
38. Telaprevir for previously untreated chronic hepatitis C virus infection.
Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
[TBL] [Abstract][Full Text] [Related]
39. Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose interferon induction therapy.
Gelderblom HC; Zaaijer HL; Dijkgraaf MG; Van Der Meer J; Weegink CJ; Jansen PL; Beld MG; Reesink HW
Scand J Gastroenterol; 2008; 43(7):857-69. PubMed ID: 18584525
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]